Victor Sierra

Most-cited papers

1. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.

   S. Biswal, C. Borja-Tabora, Luis Martinez Vargas, Hector Velásquez +22 more

   2020The Lancet221 citations Open access

   Semantic Scholar

   Save

2. Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)

   J. Altcheh, Victor Sierra, T. Ramírez, Jimy José Pinto Rocha +4 more

   2023Antimicrobial Agents and Chemotherapy13 citations Open access

   Semantic Scholar

   Save

3. Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4–6-year-old Girls: Results to Month 12 From a Randomized Trial

   Lin Lan, M. Parra, Victor Sierra, A. Cespedes +6 more

   2018The Pediatric Infectious Disease Journal11 citations

   Semantic Scholar

   Save

4. Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.

   Lan Lin, M. Macias-Parra, Victor Sierra, Albino Salas Cespedes +7 more

   2019The Pediatric Infectious Disease Journal10 citations Open access

   Semantic Scholar

   Save

5. 2128. Lack of Congenital Transmission in Infants Born of Female Patients with Chagas Disease who Became Pregnant During a Nifurtimox Study (CHICO and CHICO SECURE Study)

   A. Jaime, T. Ramírez, Victor Sierra, G. Moscatelli +4 more

   2022Open Forum Infectious Diseases1 citations Open access

   Semantic Scholar

   Save